Hemogenyx Pharmaceuticals (HEMO) Competitors GBX 343.40 +20.90 (+6.48%) (As of 12/20/2024 12:19 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines HEMO vs. BTG, ABC, ONT, GNS, ERGO, SLN, OXB, PRTC, HZD, and VRPShould you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include BTG (BTG), Abcam (ABC), Oxford Nanopore Technologies (ONT), Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), and Verona Pharma plc (VRP.L) (VRP). These companies are all part of the "biotechnology" industry. Hemogenyx Pharmaceuticals vs. BTG Abcam Oxford Nanopore Technologies Genus Ergomed Silence Therapeutics Oxford Biomedica PureTech Health Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) BTG (LON:BTG) and Hemogenyx Pharmaceuticals (LON:HEMO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Is BTG or HEMO more profitable? BTG's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BTGN/A N/A N/A Hemogenyx Pharmaceuticals N/A -155.97%-37.79% Does the media favor BTG or HEMO? In the previous week, BTG had 4 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 5 mentions for BTG and 1 mentions for Hemogenyx Pharmaceuticals. BTG's average media sentiment score of 0.12 beat Hemogenyx Pharmaceuticals' score of -1.05 indicating that BTG is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BTG 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Hemogenyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Which has higher earnings & valuation, BTG or HEMO? BTG has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBTG£914.10M0.00N/A£28.50N/AHemogenyx PharmaceuticalsN/AN/A-£5.18M-£0.01-34,340.00 Do insiders and institutionals believe in BTG or HEMO? 0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.7% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor BTG or HEMO? BTG received 564 more outperform votes than Hemogenyx Pharmaceuticals when rated by MarketBeat users. Likewise, 73.95% of users gave BTG an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBTGOutperform Votes61973.95% Underperform Votes21826.05% Hemogenyx PharmaceuticalsOutperform Votes5557.89% Underperform Votes4042.11% SummaryBTG beats Hemogenyx Pharmaceuticals on 9 of the 11 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Hemogenyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEMO vs. The Competition Export to ExcelMetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£4.60B£164.65M£5.14B£1.88BDividend YieldN/A3.64%5.09%5.54%P/E Ratio-34,340.00115.5190.051,810.29Price / SalesN/A18,239.951,117.14382,807.21Price / Cash2.0512.7543.0428.42Price / BookN/A8.504.782.91Net Income-£5.18M-£20.67M£120.31M£156.83M7 Day Performance-18.24%-1.04%-1.92%-1.92%1 Month Performance22,418.03%136.65%11.51%17.93%1 Year Performance16,252.38%137.57%30.61%29.50% Hemogenyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEMOHemogenyx PharmaceuticalsN/AGBX 343.40+6.5%N/A+15,509.1%£4.60BN/A-34,340.0014Negative NewsGap UpBTGBTGN/AN/AN/AN/A£3.26B£914.10M29.474,690News CoverageABCAbcamN/AN/AN/A+0.0%£2.81B£350.40M20,433.331,650Gap UpHigh Trading VolumeONTOxford Nanopore Technologies1.5484 of 5 starsGBX 157+1.4%GBX 235.50+50.0%-30.5%£1.48B£167.75M-774.001,281Positive NewsGNSGenus1.4639 of 5 starsGBX 1,630-0.2%GBX 2,150+31.9%-30.2%£1.07B£668.80M13,616.67480ERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386SLNSilence TherapeuticsN/AGBX 535-0.9%N/A+0.0%£480.35M£11.35M-11.01100News CoveragePositive NewsHigh Trading VolumeOXBOxford BiomedicaN/AGBX 423.50flatGBX 433.33+2.3%+115.4%£446.20M£97.28M-295.83891PRTCPureTech Health2.247 of 5 starsGBX 170+4.4%GBX 455+167.6%+0.3%£407.01M£3.33M-739.13300News CoverageHigh Trading VolumeHZDHorizon Discovery Group plc (HZD.L)N/AGBX 184.50flatN/A+0.0%£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/A+0.0%£228MN/A-1.6822News CoverageGap Up Related Companies and Tools Related Companies BTG Alternatives Abcam Alternatives Oxford Nanopore Technologies Alternatives Genus Alternatives Ergomed Alternatives Silence Therapeutics Alternatives Oxford Biomedica Alternatives PureTech Health Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:HEMO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
